0
Other Articles |

TREATMENT OF PNEUMOCOCCIC PNEUMONIA WITH SULFANILAMIDE

ALVIN E. PRICE, M.D.; GORDON B. MYERS, M.D.
JAMA. 1939;112(11):1021-1027. doi:10.1001/jama.1939.02800110001001.
Text Size: A A A
Published online

Sulfanilamide has proved bacteriostatic against types I, II, III and XIV pneumococci in vitro and in laboratory animals, according to various authors.1 While the drug probably has been used widely for human pneumococcic pneumonia, the reports to date are meager. Heintzelman, Hadley and Mellon2 used it in nine cases of type III pneumonia and obtained seven recoveries, whereas among ten controls there were only two recoveries. Millett3 reported one case of type III pneumonia in which a crisis occurred after the use of sulfanilamide. Louis4 added six cases of pneumococcic pneumonia in which recovery occurred with sulfanilamide therapy.

The following report is based on 115 patients treated with sulfanilamide.5 compared with forty patients receiving serum and ninety-four controls receiving identical symptomatic and supportive measures but no specific therapy. While this series is too small to be statistically significant, it is reported in the hope that

Topics

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs